RLYB
Rallybio
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
RLYB Profile
Rallybio Corporation
A biotech company focused on developing life-changing therapies for rare diseases
Life Science Tools and Services
03/22/2018
07/29/2021
NASDAQ Stock Exchange
25
12-31
Common stock
234 Church Street, Suite 1020, New Haven, CT 06510
--
Rallybio Corporation was incorporated in Delaware on March 22, 2018. The Company is a clinical-stage biotechnology company comprised of experienced biopharmaceutical industry leaders with extensive research, development and rare disease expertise, and its mission is to develop and commercialize life-changing therapies for patients with serious and rare diseases. Since its launch in January 2018, the company has built a broad pipeline of promising product candidates designed to address diseases with unmet medical needs in areas such as maternal and fetal health, complement disorders, hematology and metabolic disorders. Two of the company's most advanced programs are in clinical development: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (" FNAIT "), and RLYB116, an inhibitor of complement component 5 (" C5 "), which has the potential to treat several complement disorder diseases.